Aarti Drugs Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ht4e0uyvtjihms9c30s2fykj.pdf

Key Takeaways


Margin Walk: Inventory Losses and Operating Costs

Adhish Patil: "If the volatility goes away, the margins should improve considerably. And going forward, we at least expect around a couple of percent improvement going forward. And they will keep improved scenario becomes stable once all the inventory losses goes away, then the margin should improve. So at the end, we should try to, by the end in Q4, we should try to get EBITDA margins upwards of 15%."

Specialty Chemicals: Delayed Ramp, Large Ambition

Adhish Patil: "So because it is Specialty Chemical and we have been dealing in this, we will try our best to ramp up as soon as possible. So by the end of next year, hopefully we should be occupying it by the end of next financial year. But how much time it will take, we also are not very clear on that, how much we will get for the next entire year."

Demand and Volume Dynamics

Adhish Patil: "And also because the macro factors where because of this war scenario and others and everything, it was quite unclear. So we did not want to lose on production so that is why we kept on producing."

Capex and Project Updates

Adhish Patil: "So we decided that rather than spending that much, we will spend less upfront and still implement the capacity. But we are doing that project, but we are not going in we are giving up the PLI benefit because we are getting everything in capex."

Gliptins and New Product Pipelines


Competitive Position and Pricing Power

Adhish Patil: "Even when it comes to Chinese manufacturers, we have captured a lot of their market share in Southeast Asian markets as well but only the few things about ammonia. And that has affected only the Indian players and not the Chinese players. So there, it is slight out of our hands, though even though our efficiencies might be at par with them or even better."

Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin exit rateUpwards of 15%By end of Q4 FY23
High-cost inventory exhaustionImprovement visible from Q3 onwardsQ3 FY23, assuming stable input prices
Tarapur Specialty Chemicals ramp150 tonnes/month (out of 400)November 2022
Tarapur derma API GreenfieldCommence operationsBy end of FY23 (March 2023)
Baddi oral oncology plantCommence commercial operationsMarch 2023
Gujarat Greenfield facilityCommissioning and trialsEnd of Q1 FY24 (June 2023)
Two Greenfield projects capex completionMost of ~₹350 Cr spentBy June 2023
Vildagliptin meaningful export volumesExport volumes to pick upIn another 2 quarters
Formulation margin recoveryHigher-margin export orders executedComing 2 quarters
Metformin and DCDA price stabilizationDCDA to stabilize below $3,000; Metformin to stabilizeAlready stabilized "more or less"

Key Metrics

MetricQ2 FY23
Standalone revenue₹624.9 cr, +22% YoY
Consolidated revenue~₹710 cr (per an analyst's math), standalone contributed 88%
Formulation segment revenue₹82.5 cr, +9% YoY
API segment revenue growth+17% YoY
Standalone domestic revenue growth~19% YoY
Standalone export revenue growth~28% YoY
Consolidated EBITDA margin (H1 FY23)10.8%
API segment EBITDA margin11.2%, improved from 10% in Q1 FY23
Notional forex loss~₹2 cr
API volume growth (export)11%
API volume growth (domestic)Marginal
Formulation segment share of total revenue~12%
Formulation exports share of formulation revenue~44%
Standalone domestic revenue share~62%
Standalone export revenue share~38%
API therapeutic mix: antibiotic~44% of total APIs
API therapeutic mix: antidiabetic~17% of total APIs
API therapeutic mix: antiprotozoal~16% of total APIs
API therapeutic mix: anti-inflammatory~10% of total APIs
API therapeutic mix: antifungal~8% of total APIs
Metformin sales volume~1,000 tonnes per month
Metformin average capacity1,150–1,200 tonnes per month
DCDA raw material priceless than $3,000, down from $4,000–$4,500 at beginning of year
H1 FY23 capex incurred₹77 cr
FY23 capex guidance₹200–300 cr
Baddi formulation capex (total planned)₹55 cr, of which ~₹40 cr done
Baddi plant full-capacity revenue potential₹200 cr
Tarapur Specialty Chemicals Brownfield capacity achieved~60 out of 400 tonnes per month, expected to reach 150+ in November
Tarapur Specialty Chemicals Brownfield full-scale revenue potential₹90–105 cr
Existing standalone capacities full-scale revenue potentialupwards of ₹3,000 cr
Existing formulation capacities full-scale revenue potential~₹300 cr
Current capacity utilization (API and Specialty Chemicals)mid-70s%
Gujarat Greenfield capex~₹150–200 cr
Total Greenfield projects capex~₹350 cr, expected completion by June 2023
Post-Gujarat backward integration increase10–12% of finished sale further backward integrated
Ammonia price increase~3x versus one year ago
Inventory level₹500-odd cr
Production volume growth10%
Q4 FY23 EBITDA margin targetupwards of 15%